Online citations, reference lists, and bibliographies.
← Back to Search

New Insights Into The Metastatic Behavior After Breast Cancer Surgery, According To Well-established Clinicopathological Variables And Molecular Subtypes

O. Buonomo, E. Caredda, I. Portarena, G. Vanni, A. Orlandi, C. Bagni, G. Petrella, L. Palombi, P. Orsaria
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Despite advances in treatment, up to 30% of patients with early breast cancer (BC) experience distant disease relapse. However, a comprehensive understanding of tumor spread and site-specific recurrence patterns remains lacking. This retrospective case-control study included 103 consecutive patients with metastatic BC admitted to our institution (2000–2013). Cases were matched according to age, tumor biology, and clinicopathological features to 221 patients with non-metastatic BC (control group). The median follow-up period among the 324 eligible patients was 7.3 years. While relatively low values for sensitivity (71%) and specificity (56%) were found for axillary lymph node (ALN) involvement as an indicator of risk and pattern of distant relapse, nodal status remained the most powerful predictor of metastases (OR: 3.294; CL: 1.9–5.5). Rates of dissemination and metastatic efficiency differed according to molecular subtype. HER2-positive subtypes showed a stronger association with systemic spread (OR: 2.127; CL: 1.2–3.8) than other subgroups. Classification as Luminal or Non-Luminal showed an increased risk of lung and distant nodal recurrence, and a decreased risk in bone metastases in the Non-Luminal group (OR: 2.9, 3.345, and 0.2, respectively). Tumors with HER2 overexpression had a significantly high risk for distant relapse (OR: 2.127) compared with HER2-negative tumors and also showed higher central nervous system (CNS) and lung metastatic potential (OR: 5.6 and 2.65, respectively) and low risk of bone disease progression (OR: 0.294). Furthermore, we found significant associations between biological profiles and sites of recurrence. A new process of clinical/diagnostic staging, including molecular subtypes, could better predict the likelihood of distant relapses and their anatomical location. Recognition and appreciation of clinically distinct molecular subtypes may assist in evaluation of the probability of distant relapses and their sites. Our analysis provides new insights into management of metastatic disease behavior, to lead to an optimal disease-tailored approach and appropriate follow-up.
This paper references
10.1038/nature03799
Genes that mediate breast cancer metastasis to lung
A. Minn (2005)
A new genomedriven integrated classification of breast cancer and its implications
SJ Dawson (2013)
protein overexpression in breast cancer . Association with comedotype ductal carcinoma in situ and limited prognostic value in Stage II breast cancer
M vandeVijver (1988)
10.1200/JCO.1989.7.8.1120
HER-2/neu oncogene protein and prognosis in breast cancer.
A. K. Tandon (1989)
Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer
M Van De Vijver (1988)
10.1016/S0959-8049(03)00422-2
The process of metastasisation for breast cancer.
J. Engel (2003)
An immunohistochemical evaluation of cerbB2 expression in human breast carcinoma
DM Barnes (1988)
10.1038/emboj.2013.19
A new genome‐driven integrated classification of breast cancer and its implications
Sarah-Jane Dawson (2013)
Prognostic factors in breast cancer
L. Belghiti (2002)
Ten - year outcomes in a population in a populationbased cohort of nodenegative , lymphatic , and vascular invasionnegative early breast cancers without adjuvant systemic therapies
SK Chia (2004)
10.1200/JCO.2004.09.070
Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies.
S. Chia (2004)
10.1007/BF01836956
Prognostic factors and natural history in lymph node-negative breast cancer patients
R. Arriagada (2005)
10.1016/j.breast.2012.12.006
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
E. Olson (2013)
10.1002/cncr.21659
Twenty‐five years of follow‐up in patients with operable breast carcinoma
R. Arriagada (2006)
10.1007/s10549-004-1470-1
The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database
J. Rosenberg (2004)
Resistance to tamoxifeninduced apoptosis is associated with direct interaction between Her 2 / neu and cell membrane estrogen receptor in breast cancer
YL Chung (2002)
10.1016/j.breast.2008.03.004
Factors affecting the prognosis of breast cancer patients with brain metastases.
P. Saip (2008)
10.1634/theoncologist.2008-0230
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
J. Ross (2009)
10.1016/S1040-1741(12)00205-9
Effect of Very Small Tumor Size on Cancer-Specific Mortality in Node-Positive Breast Cancer
P. K. Morrow (2012)
10.1093/annonc/mdt303
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch (2013)
10.1007/s10147-011-0336-x
The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer
X. Duan (2011)
10.1038/nature05760
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
G. Gupta (2007)
10.1097/00000658-199911000-00012
Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers.
C. Gajdos (1999)
10.1038/415530a
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
A. Borg (1990)
10.1158/1078-0432.CCR-07-1658
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
M. Cheang (2008)
Twenty - five years of follow - up in operable breast cancer : Relationship between clinicopathological factors and death risk in each 5 - year period
R Arriagada (2006)
10.1016/j.breast.2012.03.004
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
A. García Fernández (2012)
10.1186/bcr2607
Breast cancer prognostic classification in the molecular era: the role of histological grade
E. Rakha (2010)
10.1200/JCO.1991.9.12.2134
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
R. Buzzoni (1991)
10.1038/sj.bjc.6601970
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
A. Clayton (2004)
10.1043/0003-9985(2000)124<0966:PFIBC>2.0.CO;2
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
P. Fitzgibbons (2000)
10.1093/OXFORDJOURNALS.ANNONC.A057824
Original article: Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer
R. Anbazhagan (1991)
Association of cerbB2 expression and S - phase fraction in prognosis of node positive breast cancer
R Anbazaghan (1991)
Clinical outcomes and treatment practice patterns of patients with HER 2positive metastatic breast cancer in the posttrastuzumab era
EM Olson (2013)
10.1002/ijc.1614
Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer
Y. Chung (2002)
For Panel Members
Denise Dunlap ETIC (2019)
10.1093/annonc/mdt287
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
F. Montemurro (2013)
Human epidermal growth factor receptor 2 ( HER 2 )positive and hormone receptorpositive breast cancer : new insights into molecular interactions and clinical implications
F Montemurro (2013)
10.1158/1078-0432.CCR-04-0220
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
10.1200/JCO.2004.01.175
CNS metastases in breast cancer.
N. Lin (2004)
10.1038/bjc.1988.238
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
D. Barnes (1988)
10.1038/nrclinonc.2009.44
Cancer micrometastases
K. Pantel (2009)
Prognostic factors and natural history in lymph nodesnegative breast cancer patients
R Arriagada (1992)
10.1001/JAMA.295.14.1658
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
D. Berry (2006)
10.1002/cncr.27581
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
N. Lin (2012)
10.1093/JNCI/84.16.1266
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
F. Spyratos (1992)
10.1056/NEJM198811103191902
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
M. J. van de Vijver (1988)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
HER - 2 / WU oncogene protein and prognosis in breast cancer
AK Tandon (1989)
10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project
R. Smalley (1977)
10.1080/02841860701678761
Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer
I. Lale Atahan (2008)
10.1200/JCO.2009.25.9820
Metastatic behavior of breast cancer subtypes.
H. Kennecke (2010)
10.1097/00006534-198911000-00055
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.
C. L. Carter (1989)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1021/pr7008127
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
J. Wulfkuhle (2008)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.7314/APJCP.2012.13.10.5081
Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
Qi-dong Ge (2012)
10.1038/sj.bjc.6605062
Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?
E. Azzato (2009)



This paper is referenced by
10.1016/j.biopha.2018.03.018
miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
Jianling Wang (2018)
10.1080/13543784.2020.1792443
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
R. Bartsch (2020)
10.3390/cancers11050637
(−)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models
A. Siddique (2019)
10.21873/anticanres.13950
Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment
O. Buonomo (2020)
10.1007/s12609-019-0299-x
Diagnosing and Managing the Malignant Axilla in Breast Cancer
K. Cox (2019)
10.12659/AJCR.913581
Spindle Cell Sarcoma Mimicking Supraclavicular Lymph Node Metastasis of Breast Cancer
S. H. Paek (2019)
10.3390/cancers12071827
Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis
G. L. Wong (2020)
10.1016/j.ijscr.2020.10.020
Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings
M. Pellicciaro (2020)
10.1186/s12957-020-01893-w
Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia
S. L. Anwar (2020)
10.21873/anticanres.13031
Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer
P. Orsaria (2018)
10.12659/AJCR.921548
Pleural Schwannoma Suspected as Metastasis of Breast Cancer
S. H. Paek (2020)
10.1177/0300891619868301
Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential
P. Orsaria (2019)
10.1158/1055-9965.EPI-18-0591
A Population-Based Study on Liver Metastases in Women with Newly Diagnosed Breast Cancer
J. Xie (2018)
Impact of HER 2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
Domagoj Kustić (2019)
10.1002/jbio.201960235
Quantitative Assessment of Distant Recurrence Risk in Early Stage Breast Cancer Using a Nonlinear Combination of Pathological, Clinical, and Imaging Variables.
Brandon S. Nichols (2020)
10.2217/fon-2018-0061
miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer.
P. Žúbor (2018)
10.1007/s10549-020-05607-4
Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers
Kristen S. Purrington (2020)
10.1080/14737140.2021.1840360
Ribociclib plus fulvestrant in the treatment of breast cancer.
P. Neven (2020)
10.1177/1176935120969696
Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach
Madhuri Saindane (2020)
10.1016/j.ebiom.2020.102793
Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome
D. Venet (2020)
10.1111/tbj.13851
Feasibility and surgical impact of Z0011 trial criteria in a single‐Institution practice
Consuelo Morigi (2020)
10.1016/j.ijscr.2020.06.074
Ulcerated breast cancer with single brain metastasis: A combined surgical approach. Clinical presentation at one year follow up – A case report
Francesca Santori (2020)
10.3390/molecules25051182
Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles
C. Day (2020)
10.21873/invivo.11884
Does Age Matter? Estimating Risks of Locoregional Recurrence After Breast-conservative Surgery
G. Vanni (2020)
10.2217/pme-2020-0070
Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology.
R. Kern (2020)
10.3390/ijms20205117
The Effects of TGF-β Signaling on Cancer Cells and Cancer Stem Cells in the Bone Microenvironment
M. Futakuchi (2019)
10.1038/s41572-019-0111-2
Breast cancer
N. Harbeck (2019)
10.3390/cancers12092638
How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?
Petr Lapčík (2020)
10.1038/s41416-019-0619-y
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
A. Darlix (2019)
10.1186/s13058-020-01311-9
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer
C. Bonneau (2020)
10.21873/invivo.11962
The Effect of Coronavirus (COVID-19) on Breast Cancer Teamwork: A Multicentric Survey.
G. Vanni (2020)
10.1002/CCR3.3380
Remarkable response to pericardial window procedure and weekly docetaxel treatment in a metastatic breast cancer patient with pericardial effusion and cardiac tamponade
Meita Ucche (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar